iBio European Patent on iBioModulator Technology Emerges From Opposition Period
05 juin 2014 08h31 HE
|
iBio, Inc.
NEWARK, DE--(Marketwired - Jun 5, 2014) - iBio, Inc. (NYSE MKT: IBIO), a leader in plant-based biotechnology for developing and manufacturing biological products, has surpassed the opposition...
iBio Receives Patent Allowance in China for Fusion Protein Compositions and Technology
24 avr. 2014 08h31 HE
|
iBio, Inc.
NEWARK, DE--(Marketwired - Apr 24, 2014) - iBio, Inc. (NYSE MKT: IBIO), a leader in plant-based biotechnology for developing and manufacturing biological products, reported the allowance...
iBio Receives Patent Allowances for Pandemic Influenza Therapeutics
27 mars 2014 08h31 HE
|
iBio, Inc.
NEWARK, DE--(Marketwired - Mar 27, 2014) - iBio, Inc. (NYSE MKT: IBIO), a leader in plant-based biotechnology for developing and manufacturing biological products, reported the allowance of two U.S....
iBio to Present at the 26th Annual ROTH Conference on March 10, 2014
04 mars 2014 08h31 HE
|
iBio, Inc.
NEWARK, DE--(Marketwired - Mar 4, 2014) - iBio, Inc. (NYSE MKT: IBIO), a leader in plant-based biotechnology for developing and manufacturing biological products, has been invited to present at the...
Phase 1 Clinical Trial Begins for Malaria Vaccine Candidate Based on iBio's Proprietary Technology
10 févr. 2014 08h31 HE
|
iBio, Inc.
NEWARK, DE--(Marketwired - Feb 10, 2014) - iBio, Inc. (NYSE MKT: IBIO), a leader in plant-based biotechnology for developing and manufacturing biological products, reported the initiation of a...
iBio Adds Biotherapeutic Product for Treatment of Fibrosis to Its Proprietary Product Pipeline
30 janv. 2014 08h31 HE
|
iBio, Inc.
NEWARK, DE--(Marketwired - Jan 30, 2014) - iBio, Inc. (NYSE MKT: IBIO), a leading provider of plant-based biotechnology for developing and manufacturing biopharmaceutical products, has added a...
iBio Receives Allowance of Patent for HPV-Related Cancer Vaccine in China
21 janv. 2014 08h31 HE
|
iBio, Inc.
NEWARK, DE--(Marketwired - Jan 21, 2014) - iBio, Inc. (NYSE MKT: IBIO), a leading provider of plant-based biotechnology for developing and manufacturing biological products, has received a notice...
iBio and Caliber Designate New Fusion Protein as Target Product Under License and Collaboration Agreement
15 janv. 2014 08h31 HE
|
iBio, Inc.
NEWARK, DE--(Marketwired - Jan 15, 2014) - iBio, Inc. (NYSE MKT: IBIO) announced today that the company and Caliber Biotherapeutics have designated a proprietary fusion protein for cancer...